Literature DB >> 23320750

Changes in serum prostate-specific antigen levels and the identification of prostate cancer in a large managed care population.

Lauren P Wallner1, Stanley K Frencher, Jin-Wen Y Hsu, Chun R Chao, Michael B Nichol, Ronald K Loo, Steven J Jacobsen.   

Abstract

OBJECTIVE: To determine whether the rate of change in total serum prostate-specific antigen (PSA) levels accurately detects prostate cancer and to evaluate whether it adds any predictive value to a single measurement of serum PSA alone, in general practice settings.
MATERIALS AND METHODS: A retrospective cohort of 219,388 community-dwelling men, aged ≥45 years, enrolled in the Kaiser Permanente Southern California health plan, with no history of prostate cancer and at least three PSA measurements, were followed from 1 January 1998 to 31 December 2007, for the development of biopsy-confirmed prostate cancer. Annual percent changes in total serum PSA levels were estimated using linear mixed models. The accuracy of prostate cancer prediction was assessed for prostate cancer overall and for aggressive disease (Gleason score ≥7) and compared with that of a single measure of PSA level using area under the receiver-operating characteristic curves (AUCs).
RESULTS: The men in this cohort experienced a mean change of 2.9% in PSA levels per year and the rate of change in PSA increased modestly with age (P ≤ 0.001). Annual percent changes in PSA accurately predicted the presence of prostate cancer (AUC = 0.963) and aggressive disease (AUC = 0.955) and had more predictive accuracy for aggressive disease than did a single measurement of PSA alone (AUC = 0.727).
CONCLUSIONS: Longitudinal measures of PSA improve the accuracy of aggressive prostate cancer detection when compared with a single measurement of PSA alone. Findings from this study provide insight into the usefulness of PSA velocity as a detection marker for aggressive prostate cancer.
© 2013 BJU International.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23320750     DOI: 10.1111/j.1464-410X.2012.11651.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  11 in total

Review 1.  Serum markers in prostate cancer detection.

Authors:  Ola Bratt; Hans Lilja
Journal:  Curr Opin Urol       Date:  2015-01       Impact factor: 2.309

2.  Prostate cancer: why is PSA velocity such a sticky concept?

Authors:  Andrew J Vickers
Journal:  Nat Rev Urol       Date:  2013-03-12       Impact factor: 14.432

Review 3.  PSA Velocity in Risk Stratification of Prostate Cancer.

Authors:  Marc A Bjurlin; Stacy Loeb
Journal:  Rev Urol       Date:  2013

4.  What explains the differences between centres in the European screening trial? A simulation study.

Authors:  Jaakko Nevalainen; Ulf-Håkan Stenman; Teuvo L Tammela; Monique Roobol; Sigrid Carlsson; Kirsi Talala; Fritz H Schröder; Anssi Auvinen
Journal:  Cancer Epidemiol       Date:  2016-11-24       Impact factor: 2.984

5.  Primary extragonadal germ cell tumor: A case report on prostate seminoma.

Authors:  Wei Zheng; Lina Wang; Deyong Yang; Kun Fang; Xiaochi Chen; Xuejian Wang; Xiancheng Li; Ziyao Li; Xishuang Song; Jianbo Wang
Journal:  Oncol Lett       Date:  2015-08-11       Impact factor: 2.967

6.  Prognostic significance of the tumour-adjacent tissue in head and neck cancers.

Authors:  Martina Raudenska; Marketa Sztalmachova; Jaromir Gumulec; Michaela Fojtu; Hana Polanska; Jan Balvan; Marek Feith; Hana Binkova; Zuzana Horakova; Rom Kostrica; Rene Kizek; Michal Masarik
Journal:  Tumour Biol       Date:  2015-07-14

7.  Fluorodeoxyglucose positron emission tomography may aid the diagnosis of aggressive primary prostate cancer: A case series study.

Authors:  Riccardo Bartoletti; Enrico Meliani; Andrea Bongini; Carlo Magno; Tommaso Cai
Journal:  Oncol Lett       Date:  2013-12-09       Impact factor: 2.967

Review 8.  Biomarkers for prostate cancer: present challenges and future opportunities.

Authors:  Pranav Sharma; Kamran Zargar-Shoshtari; Julio M Pow-Sang
Journal:  Future Sci OA       Date:  2015-12-17

9.  Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results.

Authors:  Kerri Beckmann; Danielle Crawley; Tobias Nordström; Markus Aly; Henrik Olsson; Anna Lantz; Noor Binti Abd Jalal; Hans Garmo; Jan Adolfsson; Martin Eklund; Mieke Van Hemelrijck
Journal:  JAMA Netw Open       Date:  2019-11-01

10.  Prostate-specific antigen velocity in diagnosis and prognosis of prostate cancer - a systematic review.

Authors:  Arslaan Javaeed; Sanniya Khan Ghauri; Abdellatif Ibrahim; Mohamed Fahmy Doheim
Journal:  Oncol Rev       Date:  2020-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.